Clinical Research Program

摘要：临床和翻译研究 认识到临床研究的基本性质，以及常见的弱点可能是 在许多癌症中发现，CR进一步投资于从实验室到床边的连续性。我们已经成为 围绕基于组织的研究、新型疗法和技术的主题， 转向研究者发起的试验（IIT）。CR在上次竞争性续约中被评为“优秀”， 广泛的临床和研究专业知识，涵盖所有癌症类型和成像方面的关键相关优势， 统计设计、生物标记物开发、免疫肿瘤学和基于组织研究。公司责任主题包括： 1)通过早期阶段和药物启动的临床试验开发和评估新疗法; 2） 进行基于组织的最先进的组学研究，以改善癌症治疗; 3）开发新的 诊断和治疗癌症的技术。公司责任工作的重点和未来计划包括 创新的IIT利用细胞免疫研究，在细胞免疫治疗方面的投资和成功记录 试验，将基因组学工作转化为治疗性临床试验，并结合生物标志物的开发， 新的成像和技术应用到我们的试验中。它由三位充满活力的试验者和医学科学家领导。 迪斯，米洛夫斯基，还有叶。每一个都为项目带来了一套互补的技能：早期试验（Dees）， 基因组学和新药试验（Milowsky），以及转化合作研究（Yeh）。CR专注于 集水区疾病和培训下一代临床科学家。CR成员参与 针对与北卡罗来纳州集水区特别相关的癌症的多项试验。的 CR计划由60名成员组成，他们与7个基础科学和10个临床部门有关， UNC-Chapel Hill和附属机构。在上一个资助期内，会员发表了1260份癌症- 相关文章中，34%是跨计划的，18%是计划内的（45%是合作的）。在2019年， 项目成员在癌症相关的校外资助中获得了总计1870万美元（直接成本）的赠款，包括 来自NCI的520万美元（直接成本）和490万美元的其他同行评审资金。

ABSTRACT: CLINICAL AND TRANSLATIONAL RESEARCH PROGRAM Recognizing the fundamental nature of clinical research at UNC, and that common vulnerabilities may be found across many cancers, CR has further invested in the bench-to-bedside continuum. We have become even more integrated around the themes of tissue-based research, novel therapeutics and technologies with a pivot towards investigator intiated trials (IITs). CR, rated “Outstanding” at the last competitive renewal, has broad clinical and research expertise across all cancer types and key correlative strengths in imaging, statistical design, biomarker development, immuno-oncology, and tissue-based research. CR themes include: 1) Develop and evaluate novel therapies through early phase and investigator-initiated clinical trials; 2) Conduct tissue-based state-of-the-art ‘omics research to improve cancer treatments; 3) Develop new technologies for the diagnosis and treatment of cancer. Highlights of CR work and future plans include innovative IITs leveraging UNC research, an investment and track record of success in cellular immunotherapy trials, translating genomics efforts into therapeutic clinical trials, and incorporating biomarker development, novel imaging, and technologies into our trials. It is led by three dynamic trialists and physician-scientists, Drs. Dees, Milowsky, and Yeh. Each bring a complementary skill set to the program: Early Phase trials (Dees), genomics and novel drug trials (Milowsky), and translational collaborative research (Yeh). CR focuses on catchment area diseases and on training the next generation of clinical scientists. CR members are involved in multiple trials targeting cancers of particular relevance to the catchment area, the state of North Carolina. The CR Program consists of 60 members who are associated with 7 basic science and 10 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, members published 1260 cancer- related articles, 34% were inter-programmatic and 18% were intra-programmatic (45% collaborative). In 2019, program members held grants totaling $18.7M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $4.9M other peer-reviewed funding.